Research & Funding Opportunities

Research & Funding Opportunities

Neurofibromatosis Clinic: A Report on Patient Demographics and Evaluation of the Clinic

Published online by Cambridge University Press: 08 November 2016

Read Article

Current Funding Opportunities

ERASEnf is launching a new initiative to advance meaningful clinical, translational and technological innovations that impact the management of neurofibromatosis patients. We invite research proposals from investigators and inventors designed to accelerate our understanding and/or management of neurofibromatosis.


Projects seeking support by the ERASEnf funding opportunity are to be bold but translation ready, with clearly defined milestones, a realistic endpoint, and clear impact achievable within 36 months time period. Ideas that integrate novel technologies across the spectrum of neurofibromatosis translational research and management will be considered.

Applications for the competition should describe the project and clear trajectory that will result in clinical, translational or technological advances within the 36-month funding period.

Grant Categories
Collaborative Team Grants
  • (1-2 year grants, 50-100K/year) in the following areas:
  • Quality of life
  • Patient-shared decision making
  • Supportive care
  • Innovation in care models through integration of technology
Translational Research

(2-3 year grants, 250-400K/year) in areas focused on:

  • Preclinical models of NF and therapeutic strategies
  • Genomic and molecular biology research of NF related tumors
  • Signalling pathways involved in tumor progression in NF related tumors
Favorable Criteria
  • Projects which have built meaningful and strong multidisciplinary teams and involve scientists and clinicians
  • Projects involving early career investigators (within 10 years of their appointment), allied
    health professionals and teams compromised of diverse members
  • Applicants from all accredited universities are eligible to apply.
  • Applicants can be the nominated lead in only one application\
  • At least one of the principal applicants must have a faculty appoint as a clinician or scientist, or relevant practice at an accredited university
  • Submission of applications is a two-step process requiring : (1) Letter of intent, and (2) Full application submission.

Investigators who are interested in submitting a proposal should submit a letter of intent (LOI) by October 30, 2022 at midnight EST. The letter of intent is used to identify appropriate reviewers to adjudicate the merits of the full research grant. Details about the LOI application requirements:

  • Completed registration form
  • LOI should address the project, the team and the deliverables
  • LOI should be limited to no more than two pages
  • Use the following format: 12-point Times New Roman font, single-spaced, 0.75 inch margins
  • A maximum of two pages of figures can be appended
  • Full application should be sent as a single PDF (all the documents including the original
    registration form) Selected applications will be invited to submit a longer written proposal.
    Investigators should submit the full proposal by November 30, 2022 at midnight EST.

Details about the full proposal requirements:

  • Proposal should outline the scientific strategy
  • Proposal components are:
  • Background/Rationale
  • Aims
  • Preliminary Data
  • Experimental Design and Methods
  • Project Goals and Deliverables
  • Anticipated Impact on Neurofibromatosis Patients
  • Proposal should be limited to no more than ten pages
  • The budget should be justified and appended, references appended.
  • 3 Letters of Reference